SCH44342, a non-peptidic FTI, inhibited RAS processing with nanomolar potency [123], while Lonafarnib (SCH66336) demonstrated strong selectivity and effectively suppressed tumor growth in KRAS-mutated mouse models [123, 124]. This evidence concerns the gene KRAS and neoplasm.